407 related articles for article (PubMed ID: 35712773)
1. Responsive Multivesicular Polymeric Nanovaccines that Codeliver STING Agonists and Neoantigens for Combination Tumor Immunotherapy.
Su T; Cheng F; Qi J; Zhang Y; Zhou S; Mei L; Fu S; Zhang F; Lin S; Zhu G
Adv Sci (Weinh); 2022 Aug; 9(23):e2201895. PubMed ID: 35712773
[TBL] [Abstract][Full Text] [Related]
2. Ionizable polymeric nanocarriers for the codelivery of bi-adjuvant and neoantigens in combination tumor immunotherapy.
Su T; Liu X; Lin S; Cheng F; Zhu G
Bioact Mater; 2023 Aug; 26():169-180. PubMed ID: 36883121
[TBL] [Abstract][Full Text] [Related]
3. A Cancer Nanovaccine for Co-Delivery of Peptide Neoantigens and Optimized Combinations of STING and TLR4 Agonists.
Baljon JJ; Kwiatkowski AJ; Pagendarm HM; Stone PT; Kumar A; Bharti V; Schulman JA; Becker KW; Roth EW; Christov PP; Joyce S; Wilson JT
ACS Nano; 2024 Mar; 18(9):6845-6862. PubMed ID: 38386282
[TBL] [Abstract][Full Text] [Related]
4. Engineering and Delivery of cGAS-STING Immunomodulators for the Immunotherapy of Cancer and Autoimmune Diseases.
Zhou S; Cheng F; Zhang Y; Su T; Zhu G
Acc Chem Res; 2023 Nov; 56(21):2933-2943. PubMed ID: 37802125
[TBL] [Abstract][Full Text] [Related]
5. pH-Responsive STING-Activating DNA Nanovaccines for Cancer Immunotherapy.
Zhang Y; Shen T; Zhou S; Wang W; Lin S; Zhu G
Adv Ther (Weinh); 2020 Sep; 3(9):. PubMed ID: 34337143
[TBL] [Abstract][Full Text] [Related]
6. Lymph node-targeting adjuvant/neoantigen-codelivering vaccines for combination glioblastoma radioimmunotherapy.
Su T; Zhou S; Yang S; Humble N; Zhang F; Yu G; Bos PD; Cheng F; Valerie K; Zhu G
Theranostics; 2023; 13(13):4304-4315. PubMed ID: 37649594
[TBL] [Abstract][Full Text] [Related]
7. Engineering Polymeric Prodrug Nanoplatform for Vaccination Immunotherapy of Cancer.
Zhou L; Hou B; Wang D; Sun F; Song R; Shao Q; Wang H; Yu H; Li Y
Nano Lett; 2020 Jun; 20(6):4393-4402. PubMed ID: 32459969
[TBL] [Abstract][Full Text] [Related]
8. Engineering cGAS-agonistic oligonucleotides as therapeutics and vaccine adjuvants for cancer immunotherapy.
Zhou S; Su T; Cheng F; Cole J; Liu X; Zhang B; Alam S; Liu J; Zhu G
bioRxiv; 2023 Jul; ():. PubMed ID: 37502970
[TBL] [Abstract][Full Text] [Related]
9. Rational Design of T-Cell- and B-Cell-Based Therapeutic Cancer Vaccines.
Li WH; Su JY; Li YM
Acc Chem Res; 2022 Sep; 55(18):2660-2671. PubMed ID: 36048514
[TBL] [Abstract][Full Text] [Related]
10. Self-Adjuvanted Molecular Activator (SeaMac) Nanovaccines Promote Cancer Immunotherapy.
Luo Z; He T; Liu P; Yi Z; Zhu S; Liang X; Kang E; Gong C; Liu X
Adv Healthc Mater; 2021 Apr; 10(7):e2002080. PubMed ID: 33336537
[TBL] [Abstract][Full Text] [Related]
11. MuSyC dosing of adjuvanted cancer vaccines optimizes antitumor responses.
Taylor D; Meyer CT; Graves D; Sen R; Fu J; Tran E; Mirza B; Rodriguez G; Lang C; Feng H; Quaranta V; Wilson JT; Kim YJ; Korrer MJ
Front Immunol; 2022; 13():936129. PubMed ID: 36059502
[TBL] [Abstract][Full Text] [Related]
12. Self-adjuvant Astragalus polysaccharide-based nanovaccines for enhanced tumor immunotherapy: a novel delivery system candidate for tumor vaccines.
Li N; Zhang Y; Han M; Liu T; Wu J; Xiong Y; Fan Y; Ye F; Jin B; Zhang Y; Sun G; Sun X; Dong Z
Sci China Life Sci; 2024 Apr; 67(4):680-697. PubMed ID: 38206438
[TBL] [Abstract][Full Text] [Related]
13. Endosomolytic polymersomes increase the activity of cyclic dinucleotide STING agonists to enhance cancer immunotherapy.
Shae D; Becker KW; Christov P; Yun DS; Lytton-Jean AKR; Sevimli S; Ascano M; Kelley M; Johnson DB; Balko JM; Wilson JT
Nat Nanotechnol; 2019 Mar; 14(3):269-278. PubMed ID: 30664751
[TBL] [Abstract][Full Text] [Related]
14. Self-assembly nanovaccine containing TLR7/8 agonist and STAT3 inhibitor enhances tumor immunotherapy by augmenting tumor-specific immune response.
Zhang L; Huang J; Chen X; Pan C; He Y; Su R; Guo D; Yin S; Wang S; Zhou L; Chen J; Zheng S; Qiao Y
J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34452929
[TBL] [Abstract][Full Text] [Related]
15. pH and ROS Responsiveness of Polymersome Nanovaccines for Antigen and Adjuvant Codelivery: An In Vitro and In Vivo Comparison.
Jäger E; Ilina O; Dölen Y; Valente M; van Dinther EAW; Jäger A; Figdor CG; Verdoes M
Biomacromolecules; 2024 Mar; 25(3):1749-1758. PubMed ID: 38236997
[TBL] [Abstract][Full Text] [Related]
16. Self-Assembled STING-Activating Coordination Nanoparticles for Cancer Immunotherapy and Vaccine Applications.
Sun X; Huang X; Park KS; Zhou X; Kennedy AA; Pretto CD; Wu Q; Wan Z; Xu Y; Gong W; Sexton JZ; Tai AW; Lei YL; Moon JJ
ACS Nano; 2024 Apr; 18(15):10439-10453. PubMed ID: 38567994
[TBL] [Abstract][Full Text] [Related]
17. Co-delivery of Peptide Neoantigens and Stimulator of Interferon Genes Agonists Enhances Response to Cancer Vaccines.
Shae D; Baljon JJ; Wehbe M; Christov PP; Becker KW; Kumar A; Suryadevara N; Carson CS; Palmer CR; Knight FC; Joyce S; Wilson JT
ACS Nano; 2020 Aug; 14(8):9904-9916. PubMed ID: 32701257
[TBL] [Abstract][Full Text] [Related]
18. RNA Origami Functions as a Self-Adjuvanted Nanovaccine Platform for Cancer Immunotherapy.
Yip T; Qi X; Yan H; Chang Y
ACS Nano; 2024 Feb; 18(5):4056-4067. PubMed ID: 38270089
[TBL] [Abstract][Full Text] [Related]
19. TLR9 plus STING Agonist Adjuvant Combination Induces Potent Neopeptide T Cell Immunity and Improves Immune Checkpoint Blockade Efficacy in a Tumor Model.
Castro Eiro MD; Hioki K; Li L; Wilmsen MEP; Kiernan CH; Brouwers-Haspels I; van Meurs M; Zhao M; de Wit H; Grashof DGB; van de Werken HJG; Mueller YM; Schliehe C; Temizoz B; Kobiyama K; Ishii KJ; Katsikis PD
J Immunol; 2024 Feb; 212(3):455-465. PubMed ID: 38063488
[TBL] [Abstract][Full Text] [Related]
20. Chimeric Exosomes Functionalized with STING Activation for Personalized Glioblastoma Immunotherapy.
Bao P; Gu HY; Ye JJ; He JL; Zhong Z; Yu AX; Zhang XZ
Adv Sci (Weinh); 2024 Feb; 11(6):e2306336. PubMed ID: 38072677
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
